Rosenau, France

Lionel Doumampouom-Metoul

USPTO Granted Patents = 1 

Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2016

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Lionel Doumampouom-Metoul

Introduction

Lionel Doumampouom-Metoul is a notable inventor based in Rosenau, France. He has made significant contributions to the field of pharmaceuticals, particularly in the area of cell proliferation disorders. His work has led to the development of innovative solutions that aim to improve treatment options for patients.

Latest Patents

Lionel Doumampouom-Metoul holds a patent for "Cell proliferation inhibitors and conjugates thereof." This patent discloses immunoconjugates that comprise an inhibitor of Eg5 linked to an antigen binding moiety, such as an antibody. These immunoconjugates are useful for treating cell proliferative disorders. The invention also includes novel inhibitors of Eg5 that can be utilized either alone or as part of an immunoconjugate. Furthermore, the patent provides pharmaceutical compositions that comprise these compounds and immunoconjugates, along with methods for using them in treating cell proliferation disorders. He has 1 patent to his name.

Career Highlights

Lionel Doumampouom-Metoul is associated with Novartis AG, a leading global healthcare company. His role at Novartis has allowed him to work on groundbreaking research and development projects that focus on innovative therapeutic solutions.

Collaborations

Some of his notable coworkers include Paul Andrew Barsanti and Sylvie Chamoin. Their collaboration has contributed to the advancement of research in the field of cell proliferation inhibitors.

Conclusion

Lionel Doumampouom-Metoul's contributions to the field of pharmaceuticals through his innovative patents and collaborations highlight his commitment to improving treatment options for cell proliferation disorders. His work continues to inspire advancements in medical research and development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…